TICKERNOMICS Sign up
Last Update: 2024-12-27 15:26:27
Benitec Biopharma Inc. ( BNTC ) https://benitec.com
12.00USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
BNTC
264.70%
SPY
32.66%
-74.33%
BNTC
SPY
108.59%
-89.70%
BNTC
SPY
302.52%
-99.69%
BNTC
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
121.45
53.97
0.03
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-6.32
1581.69
1.89
-39.23
0.00
-2.81
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-88036.51
-1444.00
-116879.25
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.6256
-133.44
-154.57
1.17
Other Earnings and Cash Flow Stats:
Benitec Biopharma Inc. ( BNTC ) Net Income TTM ($MM) is -19.21
Benitec Biopharma Inc. ( BNTC ) Operating Income TTM ($MM) is -20.48
Benitec Biopharma Inc. ( BNTC ) Owners' Earnings Annual ($MM) is -14.45
Benitec Biopharma Inc. ( BNTC ) Current Price to Owners' Earnings ratio is -0.95
Benitec Biopharma Inc. ( BNTC ) EBITDA TTM ($MM) is -20.35
Benitec Biopharma Inc. ( BNTC ) EBITDA Margin is -116879.25%
Capital Allocation:
Benitec Biopharma Inc. ( BNTC ) has paid 0.00 dividends per share and bought back -8.487468 million shares in the past 12 months
Benitec Biopharma Inc. ( BNTC ) has reduced its debt by 0.137 million USD in the last 12 months
Capital Structure:
Benitec Biopharma Inc. ( BNTC ) Interest-bearing Debt ($MM) as of last quarter is 0
Benitec Biopharma Inc. ( BNTC ) Annual Working Capital Investments ($MM) are 0
Benitec Biopharma Inc. ( BNTC ) Book Value ($MM) as of last quarter is 64
Benitec Biopharma Inc. ( BNTC ) Debt/Capital as of last quarter is 3%
Other Balance Sheet Stats:
Benitec Biopharma Inc. ( BNTC ) has 67 million in cash on hand as of last quarter
Benitec Biopharma Inc. ( BNTC ) has 4 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Benitec Biopharma Inc. ( BNTC ) has 10 common shares outstanding as of last quarter
Benitec Biopharma Inc. ( BNTC ) has 0 million USD of preferred stock value
Academic Scores:
Benitec Biopharma Inc. ( BNTC ) Altman Z-Score is 12.07 as of last quarter
Benitec Biopharma Inc. ( BNTC ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Benitec Biopharma Inc. ( BNTC ) largest shareholder is UBS Group AG owning 1924 shares at 0.02 ($MM) value
SUVRETTA CAPITAL MANAGEMENT, LLC; Averill Madison(an insider) Bought 4810 shares of Benitec Biopharma Inc. ( BNTC ) for the amount of $46176.00 on 2024-12-03
3.03% of Benitec Biopharma Inc. ( BNTC ) is held by insiders, and 31.85% is held by institutions
Benitec Biopharma Inc. ( BNTC ) went public on 2015-08-18
Other Benitec Biopharma Inc. ( BNTC ) financial metrics:
FCF:-14.62
Unlevered Free Cash Flow:-19.58
EPS:-1.90
Operating Margin:-88036.51
Gross Profit Margin:-1444.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-31.53
Beta:1.17
Buffet's Owners Earnings:-14.45
Price to Owner's Earnings:-0.95
About Benitec Biopharma Inc. ( BNTC ) :
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.